Avalon GloboCare Corp (ALBT)

[Quintessence]

Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Cell Malignancies

https://www.globenewswire.com/news-release/2019/09/19/1917937/0/en/Avalon-GloboCare-Announces-Initiation-of-First-in-Human-Clinical-Trial-of-its-CAR-T-Candidate-AVA-001-for-Treatment-of-B-Cell-Malignancies.html

“We have successfully evolved into an active clinical-stage company with a primary focus on immune effector cell therapy in the oncology domain. As our first-in-human clinical trial, the study of AVA-001 marks a significant milestone for Avalon. We are committed to delivering precise clinical execution and leadership in cell-based therapeutics with a strong pipeline of additional cellular immunotherapy candidates,” stated David Jin, M.D., Ph.D., President, Chief Executive Officer and Co-founder of Avalon.